BioSpace5d
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Pharm Exec6d
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...
manilatimes6d
FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
This approval marks another significant step forward," said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of ...
PMLiVE5d
Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...
Yahoo Finance6d
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam ...
Pharmabiz5d
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...
Contract Pharma6d
FDA Greenlights Roche’s Evrysdi Tablet
New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.